These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 414355)
41. [Clinical evaluations of a new antibiotic, penimepicycline (Hydrocycline) in pediatrics]. Nakazawa S; Oka S; Sato H; Hirasawa Y; Chikaoka H Jpn J Antibiot; 1969 Feb; 22(1):70-8. PubMed ID: 4977345 [No Abstract] [Full Text] [Related]
42. [Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae]. Sakata H Jpn J Antibiot; 2001 May; 54 Suppl B():96. PubMed ID: 12638154 [No Abstract] [Full Text] [Related]
43. [Mid term report of the CDTR clinical trial for PRSP and BLNAR infections]. Yokoyama M Jpn J Antibiot; 2001 May; 54 Suppl B():88-90. PubMed ID: 12638152 [No Abstract] [Full Text] [Related]
46. A comparison of cefaclor and tetracycline in the treatment of bacterial bronchitis. Hurst DJ Clin Ther; 1984; 6(2):163-9. PubMed ID: 6231104 [TBL] [Abstract][Full Text] [Related]
47. [Microbiological, pharmacokinetic and clinical studies of rokitamycin dry syrup in the pediatric field]. Motohiro T; Aramaki M; Oda K; Kawakami A; Tanaka K; Koga T; Fujimoto T; Sakata Y; Yamashita F; Suzuki K Jpn J Antibiot; 1988 Jul; 41(7):920-59. PubMed ID: 3050186 [TBL] [Abstract][Full Text] [Related]
48. [Bacteriological aspects in the mid term report of the CDTR clinical trial for PRSP and BLNAR infections]. Ubukata K Jpn J Antibiot; 2001 May; 54 Suppl B():91-5. PubMed ID: 12638153 [No Abstract] [Full Text] [Related]
49. Penicillin tolerance in beta-streptococci isolated from patients with tonsillitis. Grahn E; Holm SE; Roos K Scand J Infect Dis; 1987; 19(4):421-6. PubMed ID: 3118452 [TBL] [Abstract][Full Text] [Related]
50. Bactericidal action of an average dose of erythromycin in the bronchi. Fraschini F; Avallon R; Copponi V; Fumagalli G; Mandler F; Scaglione F; Scarpazza G Curr Med Res Opin; 1979; 6(2):111-7. PubMed ID: 38063 [TBL] [Abstract][Full Text] [Related]
51. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000]. Melo-Cristino J; Fernandes ML; Serrano N; Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155 [TBL] [Abstract][Full Text] [Related]
52. Comparison of cepharadine and cephalexin in the treatment of respiratory and urinary tract infections. Mogabgab WJ Curr Ther Res Clin Exp; 1976 Apr; 19(4):421-32. PubMed ID: 4284 [No Abstract] [Full Text] [Related]
53. [Surveillance of antimicrobial susceptibility of Streptococcus pneumoniae and Hemophilus influenzae isolated from children in Guangzhou area between 2003 and 2004]. Huang XQ; Xiao ZY; Deng L; Deng QL; Xie YQ; Yang YH Zhonghua Er Ke Za Zhi; 2006 Jun; 44(6):441-4. PubMed ID: 16836856 [TBL] [Abstract][Full Text] [Related]
55. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123 [TBL] [Abstract][Full Text] [Related]
56. [Role of thiamphenicol in the treatment of community-acquired lung infections]. Raymond J; Boutros N; Bergeret M Med Trop (Mars); 2004; 64(1):33-8. PubMed ID: 15224555 [TBL] [Abstract][Full Text] [Related]